Medical network on April 27 - April 21, the national health and family planning commission, ministry of finance, public and other seven departments jointly issued "on comprehensive opened the public hospital reform work of notice, the requirements on September 30, opened the public hospital reform in an all-round way, all the abolition of all public hospital drug addition (except traditional Chinese medicine yinpian).

The reform was determined, and the public hospital's medicine took the countdown.So, what are the major cities/regions that are most concerned about?Who is worried about their share of change?

Major city/region sales champion territory

Major cities/regional medicines sales champion distribution in 2016

Data source: PDB database, China medical industry information center

In 2016, eight pharmaceutical companies accounted for 22 cities/regional sales champions.Jilin sihuan pharmaceutical co., LTD. Dominates the three major cities in northeast China.And 3 and the pearl river delta region sales first respectively by liaoning dalian Pfizer pharmaceutical co., LTD., jiangsu hengrui pharmaceutical co., LTD., Novartis Novartis and AstraZeneca (AstraZeneca).

Who is the main adversary?

The most stressful public hospitals are those who sell "old two".On the whole, the race of one or two is always the familiar name, but it is the difference between a few places in different places.Here is remarkably, Sanofi (Sanofi) in 2016 in the urban landscape seems more suitable for the name of the "second", although the champion list is missing, but here is a 5 times, and "bite" very tight.

The "second" distribution of pharmaceutical sales in the major cities of 2016

In any case, what will happen to the drug sales landscape in 2017, as the reform of public hospitals pushes back?We'll see.